Oragenics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum
January 26 2022 - 7:30AM
Business Wire
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the
“Company”) announced that the Company’s reconvened Annual Meeting
of Shareholders (the “Annual Meeting”), on January 25, 2022, at
4:00 p.m. was convened and again adjourned, without any business
being conducted, due to lack of the required quorum.
A quorum consists of a majority of the shares entitled to vote.
There were fewer than a majority of shares entitled to vote
present, either in person or by proxy at this meeting. The Annual
Meeting therefore had no quorum and the meeting was again adjourned
to 4:00 p.m. (Eastern Time) on Friday, February 25, 2022 at the
offices of Shumaker, Loop, & Kendrick, Bank of America Plaza,
101 E Kennedy Blvd., Suite 2800, Tampa, FL 33602 to allow
additional time for the Company’s shareholders to vote on the
proposals set forth in the Company’s definitive proxy statement
filed with the United States Securities and Exchange Commission
(the “SEC”) on October 13, 2021.
During the current adjournment, the Company expects to continue
to solicit votes from its shareholders with respect to the
proposals set forth in the Company’s proxy statement. As set forth
in the proxy statement, the Company has engaged a proxy solicitor,
Alliance Advisors to assist management with obtaining adequate
votes to achieve the required quorum of at least a majority of the
outstanding shares of Common Stock.
Only shareholders of record, as of the record date, October 1,
2021, are entitled to and are being requested to vote. At the time
the Annual Meeting was again adjourned, proxies had been submitted
by stockholders representing approximately 40% of the shares of the
Company’s common stock outstanding and entitled to vote at the
Annual Meeting. Proxies previously submitted in respect of the
Annual Meeting will be voted at the adjourned Annual Meeting unless
properly revoked, and stockholders who have previously submitted a
proxy or otherwise voted need not take any action.
The Company encourages all shareholders of record on October 1,
2021, whom have not yet voted, to do so by February 24, 2022 at
11:59 p.m. (Eastern Time). Shareholders who have any questions or
require any assistance with completing a proxy or voting
instruction form or who do not have the required materials, may
contact Alliance Advisors, using the following contact information:
200 Broadacres Drive, 3rd Fl., Bloomfield, NJ 07003, Telephone:
Toll Free: 1-855-723-7816 and Outside North America: 1-973-873-7700
Email: OGEN@allianceadvisorsllc.com.
If the number of additional shares of common stock voted at the
adjourned Annual Meeting is not sufficient to reach a quorum, the
Company may seek to adjourn the Annual Meeting again, which will
require the Company to incur additional costs.
Important Information
This material may be deemed to be solicitation material in
respect of the Annual Meeting to be reconvened and held on February
25, 2022. In connection with the Annual Meeting, the Company filed
a definitive proxy statement with the SEC on October 13, 2021.
BEFORE MAKING ANY VOTING DECISIONS, SECURITY HOLDERS ARE URGED TO
READ THE DEFINITIVE PROXY STATEMENT AND ANY OTHER RELEVANT
DOCUMENTS FILED WITH THE SEC, BECAUSE THEY CONTAIN IMPORTANT
INFORMATION ABOUT THE ANNUAL MEETING. The definitive proxy
statement was mailed to shareholders who are entitled to vote at
the Annual Meeting. No changes have been made in the proposals to
be voted on by stockholders at the Annual Meeting. The Company’s
proxy statement and any other materials filed by the Company with
the SEC can be obtained free of charge at the SEC's website at
sec.gov or the Company’s website
https://ir.oragenics.com/all-sec-filings.
About Oragenics, Inc.
Oragenics, Inc. is a development-stage company dedicated to
fighting infectious diseases including coronaviruses and
multidrug-resistant organisms. Its lead product is Terra CoV-2, a
vaccine candidate to prevent COVID-19 and variants of the
SARS-CoV-2 virus. The Terra CoV-2 program leverages coronavirus
spike protein research licensed from the National Institute of
Health and the National Research Council of Canada with a focus on
addressing supply-chain challenges, and offering more
patient-friendly administration, such as intranasal. Its
lantibiotics program features a novel class of antibiotics against
infectious diseases that have developed resistance to commercial
antibiotics.
For more information about Oragenics, please visit
www.oragenics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220126005376/en/
Oragenics, Inc. Michael Sullivan, Interim Principal
Executive Officer and Chief Financial Officer 813-286-7900
msullivan@oragenics.com or LHA Investor Relations Kim
Golodetz 212-838-3777 kgolodetz@lhai.com
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024